Clincosm LogoSign in Get a demo

IPNSAE: Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Unknown status
CT.gov ID
NCT03957616
Collaborator
(none)
600
Enrollment
1
Location
2
Anticipated Duration (Months)
294.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study aims to provide an estimate of the incidence of paraneoplastic neurological syndromes and autoimmune encephalitides in France between the years 2016 and 2018. The study will describe the incidence of antibody subtypes and regional variations.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    600 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis in France Between 2016 and 2018
    Anticipated Study Start Date :
    May 30, 2019
    Anticipated Primary Completion Date :
    May 30, 2019
    Anticipated Study Completion Date :
    Jul 31, 2019

    Arms and Interventions

    Arm Intervention/Treatment
    Paraneoplastic neurological syndromes patients

    Patients tested for Paraneoplastic neurological syndromes (PNS) and Autoimmune Encephalitis (AE) with a lumbar puncture, with detection of an antibody or negative, but with PNS clinically diagnosed.

    Outcome Measures

    Primary Outcome Measures

    1. Incidence and prevalence of diagnosed Paraneoplastic Neurological Syndromes (PNS) and Autoimmune Encephalitis (AE) between 2016 and 2018. [3 years]

      Comparison between general population of the French counties and the cohort of PNS to calculate incidence and prevalence.

    Secondary Outcome Measures

    1. Location (city) of diagnosis [1 hour]

      Name of city where the diagnosis of Paraneoplastic Neurological Syndromes (PNS) or Autoimmune Encephalitis (AE) was made.

    2. French general population of each counties [3 years]

      Person years for each region

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Clinical diagnosis of Paraneoplastic Neurological Syndrome (PNS) or Autoimmune Encephalitis (AE) made by the referring physician to the national center for PNS and AE in Lyon between 2016 and 2018
    Exclusion Criteria:

    • Data on location of diagnosis missing

    • Patients diagnosed out of the mainland French territory

    • Patients for whom insufficient data was available

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes Lyon France 69003

    Sponsors and Collaborators

    • Hospices Civils de Lyon

    Investigators

    • Principal Investigator: Jérôme Honnorat, center for paraneoplastic neurological syndromes and autoimmune encephalitis

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hospices Civils de Lyon
    ClinicalTrials.gov Identifier:
    NCT03957616
    Other Study ID Numbers:
    • IPNSAE
    First Posted:
    May 21, 2019
    Last Update Posted:
    May 21, 2019
    Last Verified:
    May 1, 2019
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Encephalitis
    Hashimoto Disease
    Syndrome

    Study Results

    No Results Posted as of May 21, 2019